Explore Over 11,000+ Conditions, Medications, and Symptoms.
Get a personalized feed by signing up for free.
All Conditions
Fibroadipose vascular anomaly
by Alike Medical Team ∙ Updated on June 13, 2023
This group contains additional names: - FAVA - Dabska tumor - Fibro-adipose vascular anomaly
Fibroadipose vascular anomaly (FAVA), also known as fibro-adipose vascular anomaly or Dabska tumor is a vascular anomaly that is characterized by the abnormal growth of fibrous tissue, adipose tissue, and blood vessels. It typically presents as a soft, compressible mass that may be red, purple, or blue in color. FAVA can occur anywhere on the body, but it is most commonly found in the extremities.
1 people with Fibroadipose vascular anomaly
The main symptom of FAVA is the presence of a soft, compressible mass that may be painful or tender to the touch. The mass may also be red, purple, or blue in color and may grow over time.
The diagnosis of FAVA is usually made based on a physical examination and imaging tests, such as an ultrasound or magnetic resonance imaging (MRI) scan. A biopsy may also be performed to confirm the diagnosis.
Treatment for FAVA usually involves surgical excision of the mass. In some cases, sclerotherapy or embolization may be used to shrink the size of the mass before surgery. Radiation therapy may also be used in some cases.
☝ We provide information on prescription and over-the-counter medicines, diagnosis, procedures and lab tests. This material is provided for educational purposes only and is not medical advice, diagnosis or treatment.
National Institutes of Health ∙ World Health Organization ∙ MedlinePluse ∙ Centers for Disease Control and Prevention
☝ All information has been reviewed by certified physicians from Alike
Alike is a transformative platform that goes beyond just bringing together patients; it meticulously connects individuals based on multiple critical factors, such as age, gender, comorbidities, medications, diet, and more, fostering a community of knowledge, support and empathy.
© 2020-2024 Alike, Inc